SS Innovations International stock
SSIINASDAQSS Innovations International, Inc., HealthcareISIN US05453U2033
28Score 28 out of 100, Weak
Price and trend
27 / 100
Price history
−78% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 60% below it.
Since July 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 26).
The price is 78% below its 52-week high. Largest decline in 2 years: 87% (April 2025 to November 2026).
Chart figures for advanced users
- SMA 50$2.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.74
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)26
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.51
- The lowest closing price of the last twelve months.
- Resistance$6.77
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SS Innovations International, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $302.72M, is number 89 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $42.48M (up 105.7% year on year) and a loss of $12.13M.
- MEQIRI Score 28 out of 100 (Weak): rank 708 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Share price fell sharplyDown 78% over the last 12 months.Momentum 12
- Loss-makingLoss of $12.43M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 49
The score is held back by fundamentals and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue rose 39.4% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 106% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 46%, operating −19%, net −29%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
Fiscal 2025Debt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 13 Aug 2026EPS reported −$0.01 (expected −$0.01)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.060.0%
- Revenue
- $59.6M0.0%
- Earnings per share
- −$0.060.0%
- Revenue
- $76.2M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $99,999 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sudhir SrivastavaSale
4 Sept 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 33,333
- Price
- $3.00
- Value
- $99,999
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at SS Innovations International
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 28
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Metall ZugMETN.SW $460.48M38
- NeuroPaceNPCE $429.74M34
- CerusCERS $428.14M36
- ImplanticaIMP-A-SDB.ST $393.83M49
- StratecSBS.DE $353.7M52
- CapsoVisionCV $333.63M41
- Treace Medical ConceptsTMCI $331.73M48
- InfuSystem HoldingsINFU $300.35M69
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.